Overview

* Karyopharm Q2 2025 total revenue declines to $37.9 mln from $42.8 mln in 2024

* U.S. XPOVIO net product revenue rises 6% yr/yr to $29.7 mln

* Company reaffirms 2025 total revenue guidance, updates XPOVIO revenue forecast

* Exploring financing and strategic alternatives to extend cash runway

Outlook

* Karyopharm reaffirms 2025 total revenue guidance of $140 mln to $155 mln

* Company updates 2025 U.S. XPOVIO revenue guidance to $110 mln to $120 mln

* Karyopharm exploring financing and strategic alternatives to extend cash runway

* Top-line results for SENTRY trial expected in March 2026

Result Drivers

* XPOVIO SALES - U.S. XPOVIO net product revenue rose 6% yr/yr to $29.7 mln, driven by consistent demand and community setting

* ROYALTY REVENUE - Expanded global patient access for selinexor increased royalty revenue by 28% yr/yr to $1.6 mln

* LICENSE REVENUE DECLINE - Total revenue impacted by decrease in license revenue due to non-recurring items in prior year

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $29.68

Product mln

Revenue

Q2 Net -$37.25

Income mln

Q2 $62.32

Operatin mln

g

Expenses

Q2 -$24.39

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Karyopharm Therapeutics Inc ( KPTI ) is $15.00, about 73.7% above its August 8 closing price of $3.94

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)